Clinical trials
Glioma clinical trials
Below are recruiting glioma clinical trials, each written for real people, not researchers. We’re tracking 339 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
San Francisco, CaliforniaAges 2–21 - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24 - NCT06773481RecruitingPhase 1
BC008-1A injection for recurrent grade 4 glioma
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06838676RecruitingPhase 2
ACT001 for DIPG and H3K27-altered high-grade gliomas
This trial tests a drug called ACT001 for people with diffuse intrinsic pontine glioma (DIPG) or certain high-grade gliomas that have a specific genetic change (H3K27-altered). It includes two groups: one for newly diagnosed DIPG after radiation, and another for progressive or recurrent disease.
Aurora, ColoradoAges 1–39 - NCT01106794Recruiting
Test of tumor sample analysis for brainstem glioma
This trial analyzes tumor tissue or samples to learn more about brainstem gliomas, including a common type called diffuse intrinsic pontine glioma. The results may help doctors better understand these tumors and guide future treatments.
Washington D.C., District of ColumbiaAges Up to 21 years - NCT07480941RecruitingPhase 1
CAR-NK cell therapy for recurrent glioblastoma
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
Shenzhen, GuangdongAges 18–75 - NCT07506239Recruiting
Laser therapy for low-grade brain tumors in young people
This trial tests a laser treatment called LITT for low-grade glioma (a type of brain tumor) that has come back or is growing despite prior treatment. It aims to see if the laser is safe and effective in young people aged 2 to 25.
San Francisco, CaliforniaAges 2–25 - NCT07541781RecruitingPhase 1
Sitagliptin for recurrent grade 4 glioma
This trial tests whether the diabetes drug sitagliptin (Januvia) can help slow or shrink a recurrent grade 4 glioma (a type of brain tumor). It's for people whose tumor has come back after standard treatment and who have not used sitagliptin or Avastin before.
Iowa City, IowaAges 18 years+ - NCT07551336RecruitingPhase 1
CAR-NK cells for recurrent glioblastoma and high-grade brain tumors
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
Shenzhen, GuangdongAges 18–75 - NCT07567196Recruiting
PET imaging to guide surgery for aggressive brain tumors
This trial tests whether using a special PET scan (a type of imaging that shows tumor activity) during brain tumor surgery helps doctors remove more of the tumor safely. You would have a high-grade glioma (an aggressive brain cancer) and be scheduled for surgery.
Torino, TurinAges 18 years+ - NCT07589257RecruitingPhase 2
VRT106 drug combined with radiation for brain stem tumors
This trial tests whether a new drug called VRT106, given alongside radiation therapy, can help treat a serious type of brain tumor called diffuse midline glioma or DIPG. The drug is designed to work with radiation to fight the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07074756Recruiting
Home-based treatment support for people with glioma
This study tests a digital platform that helps you manage your glioma treatment at home. It aims to make it easier to follow your treatment plan and stay connected with your care team.
Jacksonville, FloridaAges 18 years+ - NCT06660056RecruitingPhase 1
GC001 injection for returning or growing high-grade brain tumors
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06253234RecruitingPhase 1
DC vaccine for recurrent high-grade gliomas
This trial tests a vaccine made from your own immune cells (dendritic cells) to see if it can help control recurrent or progressive high-grade gliomas. It is for people whose brain tumor has returned after standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT02358187RecruitingPhase 2
Vaccine for children and teens with low-grade brain tumors
This trial tests a peptide vaccine plus a medication called poly-ICLC for people with certain low-grade gliomas that cannot be fully removed. The goal is to help the immune system recognize and attack the tumor.
Pittsburgh, PennsylvaniaAges 1–21 - NCT06444412RecruitingPhase 2
Testing a new PET scan to detect brain tumor recurrence
This trial tests a special imaging scan called Ga-68 PSMA-11 PET/CT to see if it can better detect when a glioma brain tumor has come back or progressed. It is for people who have already had standard treatment and are planning surgery for a suspected recurrence.
Rochester, MinnesotaAges 18 years+ - NCT06018363RecruitingPhase 1/Phase 2
Cell therapy for recurrent high-grade glioma
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
Suzhou, JiangsuAges 18–70 - NCT05099003RecruitingPhase 1/Phase 2
Selinexor plus radiation for newly diagnosed brain tumors
This trial studies whether adding selinexor to standard radiation can improve outcomes for children and young teens with certain newly diagnosed high-grade brain tumors (including DIPG). It’s designed for specific tumor types and genetic markers, and people must be able to start treatment soon after diagnosis.
Birmingham, AlabamaAges 1–21 - NCT07710690RecruitingPhase 1
Study of NRG-103 injection for recurrent high-grade glioma
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
ShanghaiAges 18 years+ - NCT03684109Recruiting
MRI scans to study brain tumors using molecular imaging
This study uses special MRI scans to better “characterize” (study) gliomas, a type of brain tumor, using information from your brain tissue. You may be eligible if you’re an adult with a suspected or confirmed glioma and you already need a biopsy or surgery.
Miami, FloridaAges 18 years+ - NCT03728673RecruitingPhase 2
Escitalopram for people with newly diagnosed grade 4 brain tumors
This trial studies whether escitalopram (an antidepressant medication) can help people with grade 4 glioma around the time they start standard cancer treatment. You may be screened especially for depression/anxiety status and medication history, because the study uses a specific mental-health medicine.
Omaha, NebraskaAges 19 years+ - NCT04065776Recruiting
Proton therapy that avoids the hippocampus for slow brain tumors
This study tests a proton radiation plan designed to spare the hippocampus (a memory area) in children and teens with certain low-grade brain tumors. It may help deliver treatment to the tumor while reducing unwanted brain effects.
Rochester, MinnesotaAges 6–21 - NCT04135807RecruitingEarly Phase 1
Implantable device test for operable brain tumor patients
This early-phase trial tests a tiny implanted device placed during brain tumor surgery. It delivers very small doses of medicine directly to the tumor area for a short time, aiming to see if this approach is safe and workable in patients with certain gliomas.
Boston, MassachusettsAges 18 years+ - NCT04215211Recruiting
AI tool to predict survival in people with glioma
This trial uses brain scan images (MRI) and tumor tissue tests to predict how long people with primary glioma may live. The goal is to see if the AI prediction can improve planning and care after surgery.
Zhengzhou, HenanAges 1–90
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioma?
- Yes. Clin2 currently lists 339 recruiting glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.